URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
UroGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]
UroGen Pharma to Participate at Upcoming Investor Conferences
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy [Yahoo! Finance]
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
Form SC 13G/A UroGen Pharma Ltd. Filed by: BlackRock Inc.
Form 10-K/A UroGen Pharma Ltd. For: Dec 31
Form 4 UroGen Pharma Ltd. For: Mar 18 Filed by: Schoenberg Mark
Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
Form 10-K UroGen Pharma Ltd. For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.